E28.2
Conditions
Interventions
Group 1: A total of 15 patients will be examined. 5 with a BMI 30.
Group 2: Five Patients who are healthy serve as a control group.
Sponsors
Chemogroup
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Female patients, age = 18 and = 45 years old 2. PCO Syndrome according to the Rotterdam criteria 3. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Current BMI <20 kg/m2 2. Patients with severe acute or chronic diseases (e.g. pancreatitis, hypertriglyceridemia, liver disease, benign or malignant liver tumour, malignant sex hormone-dependent diseases of genitals or breasts). 3. Migraines 4. Intake of herbal medicines that induce microsomal enzymes, in particular cytochrome P450 enzyme, e.g. phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, topiramate, felbamate, griseofulvin, some HIV protease inhibitors (e.g. ritonavir) and non-nucleoside reverse transcriptase inhibitors (e.g. efavirenz) and preparations of Aaron. 5. History of cardiovascular events 6. Advanced hypertension or Diabetes 7. Presence or known Risk of venous or arterial thromboembolism 8. Undiagnosed abnormal vaginal bleeding 9. Use of medical products which contain Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir during two weeks before the start of the study 10. Pregnancy and lactation throughout the study period 11. Patients who are postmenopausal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Auswertung der inflammatorischen und resolutiven Plasma und Serum Parameter bei PCOs Patientinnen. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Germany
Contacts
Public ContactPedro-Antonio Regidor
Exeltis Healthcare
Outcome results
None listed